Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
We know from a number of older, epidemiologic studies that there seems to be an inverse association between diabetes status and prostate cancer risk. In other words, people with diabetes seem to be less likely to be diagnosed with prostate cancer.
Filed under: Diagnosis, Prevention, Risk | Tagged: allele, diabetes, genetics, genome, risk | Leave a Comment »
In March 2010, as previously reported on this web site, a federal court judge initially ruled that the patents on the BRCA1 and BRCA2 genes held by Myriad Genetics and the University of Utah “are directed to a law of nature and were therefore improperly granted.”
Filed under: Diagnosis, Management | Tagged: BRCA, gene, Myriad Genetics, patent | Leave a Comment »
Proving the point that (at least in prostate cancer) if you look carefully enough you can always find a study that supports your particular point of view, a new report from researchers at the National Institutes of Health and partner organizations has now demonstrated that, “High blood levels of vitamin D may increase a man’s [...]
Filed under: Living with Prostate Cancer, Management, Prevention | Tagged: 25-hydroxy, risk, supplement, vitamin D | 4 Comments »
A new report in European Urology may offer some insights into the value of large, retrospective data analyses as compared to multi-center, randomized clinical trials when it comes to the assessment of the effects of different first-line treatments on the management of clinically localized prostate cancer.
Filed under: Management, Treatment, Uncategorized | Tagged: age, mortality, observation, radical prostatectomy, watchful waiting | 5 Comments »
Terry Herbert — the founder and organizer of the YANA web site — has announced that he will be closing down the Experiences section of YANA at some time in the near future. After coordinating the YANA site for most of the past 15 years, Terry has (appropriately) decided it is time for him to [...]
Filed under: Living with Prostate Cancer | Tagged: advocacy, Herbert, YANA, Yananow | 14 Comments »
In a new paper just published on-line in the Journal of Urology, Kapoor et al. have provided data on trends in the utilization of various major types of treatment for the management of localized prostate cancer among Medicare beneficiaries in the USA between 2006 and 2008.
Filed under: Management, Treatment | Tagged: beneficiary, cryotherapy, Medicare, radiation, surgery, Treatment, utilization | Leave a Comment »
A conversation between two extremely knowledgeable prostate cancer advocates in comments on an earlier post has highlighted the underlying problem of what we mean by “over-diagnosis” and “over-treatment” of prostate cancer in a highly educational manner.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: over-diagnosis, over-treatment, risk | 9 Comments »
An Australian research team has used data from 148 men from 1,423 families identified through the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab) to assess the risks associated with prostate cancer in males from breast cancer-prone families, and most particularly from those families in which the BRCA2 gene mutation is prevalent.
Filed under: Diagnosis, Management, Risk | Tagged: BRCA mutation, family, outcome, risk | Leave a Comment »
Last Friday the European Medicines Agency (EMEA) gave approval for the marketing of abiraterone acetate (Zytiga™) for the treatment of metastatic, castration-resistant prostate cancer in men who have already progressed after treatment with docetaxel-based chemotherapy.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, approval, Europe, Zytiga | Leave a Comment »
A new review by Epstein, currently available on line in the Journal of Urology, provides a detailed analysis of the clinical significance of various factors in determining prognostic risk for newly diagnosed and recently treated patients with localized prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, clinical, core, pathologic, prognosis, quantification, stage, T2, tumor, volume | 10 Comments »
Back in March, a group of authors from three major medical centers published a report in the Journal for Healthcare Quality strongly suggesting that U.S. hospitals were inappropriately over-promoting the use of robot-assisted surgery for treatment of prostate cancer.
Filed under: Management, Treatment | Tagged: hospital, outcome, promotion, radical prostatectomy, RALP, volume | Leave a Comment »
A new study just published in The Lancet has reported that — among men who have urinary incontinence 6 weeks after a radical prostatectomy (RP) — formal one-on-one training of patients by expert therapists does not in fact reduce the rate of continence at 12 months compared to patients in a control group.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: continence, exercises, incontinence, Kegel, outcome, radical prostatectomy, randomized, training, trial | 4 Comments »
The U.S. News and World Report has issued its regular list of “top hospitals” around the nation for 2011/12.
Filed under: Uncategorized | Tagged: hospitals, top | 1 Comment »
Based on data collected in the Cryo On-Line Database (COLD), Dhar et al. have just published an analysis of data from a total of 860 men, all over 75 years of age, who were treated with whole-gland cryoablation for clinically localized prostate cancer at times dating back to at least 1995.
Filed under: Diagnosis, Management, Risk, Uncategorized | Tagged: croablation, cryotherapy, elderly, outcome, risk, whole-gland | 1 Comment »
A forthcoming paper from Tewari’s group at Weill Cornell Medical College in New York describes a new set of nomograms for assessment of risk for worsening prognosis in men with localized prostate cancer who might otherwise be considered appropriate candidates for management under active surveillance.
Filed under: Diagnosis, Management, Risk | Tagged: active surveillance, candidate, nomogram, prognosis, risk | 9 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site